Rezolute(US:RZLT) Globenewswire·2026-01-03 12:41Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. following a significant drop in its stock price due to disappointing clinical trial results for its lead drug candidate, ersodetug [4][5]. Group 1: Company Overview - Rezolute, Inc. is a biopharmaceutical company listed on NASDAQ under the ticker RZLT [4]. - The company focuses on developing treatments for congenital hyperinsulinism, with ersodetug being its lead drug candidate [5]. Group 2: Recent Developments - On December 11, 2025, Rezolute's shares fell sharply after the Phase 3 sunRIZE clinical trial results for ersodetug failed to meet primary and key secondary endpoints [5]. - The highest dose in the trial showed reductions in hypoglycemia events that were not statistically significant compared to placebo [5]. Group 3: Stock Performance - During intraday trading on December 11, 2025, Rezolute's stock price plummeted from approximately $10.94 to an intraday low of around $0.90, marking an approximate 85-90% decline [6].